SLGL
Sol-Gel Technologies Ltd. [SLGL] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SLGL Stock Summary
Top 10 Correlated ETFs
SLGL
Top 10 Correlated Stocks
SLGL
In the News
SLGL Financial details
Company Rating
Neutral
Market Cap
23.4M
Income
-47.65M
Revenue
2.01M
Book val./share
1.39
Cash/share
1.36
Dividend
-
Dividend %
-
Employees
36
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-0.7
Forward P/E
-
PEG
-0.03
P/S
20.08
P/B
0.77
P/C
0.69
P/FCF
15.88
Quick Ratio
9.61
Current Ratio
10.09
Debt / Equity
0.04
LT Debt / Equity
0.03
-
-
EPS (TTM)
-1.85
EPS next Y
-
EPS next Q
-
EPS this Y
71.19%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-4.33%
Revenue last 5Y
-41.61%
Revenue Q/Q
109.86%
EPS Q/Q
-19.05%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
29.02%
Inst Trans
0.92%
ROA
-96%
ROE
-108%
ROC
-0.19%
Gross Margin
100%
Oper. Margin
-507%
Profit Margin
-2868%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.79-4.2
52W High
-
52W Low
-
RSI
46
Rel Volume
0.37
Avg Volume
31.01K
Volume
11.44K
Perf Week
12.27%
Perf Month
-14.22%
Perf Quarter
-29.05%
Perf Half Y
-37.09%
-
-
-
-
Beta
1.324
-
-
Volatility
0.04%, 0.08%
Prev Close
4.83%
Price
0.9436
Change
10.12%
SLGL Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.17 | 0.39 | 1.36 | 0.17 | 0.06 | |
| Net income per share | -1.26 | -1.21 | 0.19 | -0.59 | -1.01 | |
| Operating cash flow per share | -1.15 | -1.12 | -0.33 | -0.41 | -0.65 | |
| Free cash flow per share | -1.18 | -1.14 | -0.34 | -0.42 | -0.66 | |
| Cash per share | 2.58 | 2.22 | 1.87 | 1.45 | 1.4 | |
| Book value per share | 2.69 | 2.25 | 2.41 | 1.83 | 1.43 | |
| Tangible book value per share | 2.69 | 2.25 | 2.41 | 1.83 | 1.43 | |
| Share holders equity per share | 2.69 | 2.25 | 2.41 | 1.83 | 1.43 | |
| Interest debt per share | 0.1 | 0.09 | 0.07 | 0.09 | 0.06 | |
| Market cap | 335.02M | 221.01M | 170.67M | 105.46M | 30.07M | |
| Enterprise value | 327.65M | 215.86M | 152.18M | 93.79M | 24.21M | |
| P/E ratio | -13.61 | -8.07 | 39.16 | -7.75 | -1.1 | |
| Price to sales ratio | 14.63 | 25.2 | 5.46 | 27.16 | 19.35 | |
| POCF ratio | -14.89 | -8.76 | -22.19 | -11.12 | -1.7 | |
| PFCF ratio | -14.5 | -8.6 | -21.79 | -10.92 | -1.68 | |
| P/B Ratio | 6.39 | 4.35 | 3.07 | 2.5 | 0.78 | |
| PTB ratio | 6.39 | 4.35 | 3.07 | 2.5 | 0.78 | |
| EV to sales | 14.31 | 24.61 | 4.87 | 24.15 | 15.58 | |
| Enterprise value over EBITDA | -13.07 | -7.14 | 51.34 | -5.98 | -0.83 | |
| EV to operating cash flow | -14.56 | -8.55 | -19.79 | -9.89 | -1.37 | |
| EV to free cash flow | -14.19 | -8.4 | -19.43 | -9.71 | -1.36 | |
| Earnings yield | -0.07 | -0.12 | 0.03 | -0.13 | -0.91 | |
| Free cash flow yield | -0.07 | -0.12 | -0.05 | -0.09 | -0.59 | |
| Debt to equity | 0.04 | 0.04 | 0.03 | 0.02 | 0.04 | |
| Debt to assets | 0.03 | 0.03 | 0.02 | 0.02 | 0.04 | |
| Net debt to EBITDA | 0.29 | 0.17 | -6.24 | 0.74 | 0.2 | |
| Current ratio | 8.58 | 8.95 | 4.88 | 12.93 | 9.1 | |
| Interest coverage | 0 | 0 | 0 | -12.3 | 0 | |
| Income quality | 0.91 | 0.86 | -2.39 | 0.64 | 0.65 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.36 | 1.26 | 0.27 | 1.92 | 4.74 | |
| Research and developement to revenue | 1.77 | 3.18 | 0.65 | 3.27 | 15.15 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.03 | 0.02 | 0.02 | 0.02 | 0.01 | |
| Capex to revenue | -0.03 | -0.05 | 0 | -0.04 | -0.09 | |
| Capex to depreciation | -0.67 | -0.47 | -0.16 | -0.3 | -0.39 | |
| Stock based compensation to revenue | 0.11 | 0.14 | 0.02 | 0.39 | 1.2 | |
| Graham number | 8.73 | 7.84 | 3.2 | 4.91 | 5.68 | |
| ROIC | 0.46 | -0.52 | 0.05 | -0.34 | -0.71 | |
| Return on tangible assets | -0.4 | -0.46 | 0.06 | -0.29 | -0.6 | |
| Graham Net | 2.28 | 1.93 | 1.71 | 1.52 | 1.17 | |
| Working capital | 49.29M | 47.44M | 45.42M | 39.73M | 36.65M | |
| Tangible asset value | 52.47M | 50.85M | 55.59M | 42.21M | 38.64M | |
| Net current asset value | 46.96M | 45.09M | 43.51M | 38.64M | 34.52M | |
| Invested capital | 0.04 | 0.04 | 0.03 | 0.02 | 0.04 | |
| Average receivables | 2.06M | 3.14M | 7.61M | 10.46M | 4.12M | |
| Average payables | 2.32M | 1.46M | 984.5K | 508.5K | 202.5K | |
| Average inventory | 0.5 | 0.5 | 0.5 | 1 | 0.5 | |
| Days sales outstanding | 65.66 | 89.6 | 152.49 | 738.65 | 88.55 | |
| Days payables outstanding | 15.38 | 15.73 | 13.72 | 7.22 | 164.36 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 5.56 | 4.07 | 2.39 | 0.49 | 4.12 | |
| Payables turnover | 23.73 | 23.2 | 26.61 | 50.53 | 2.22 | |
| Inventory turnover | 40.58M | 0 | 20.38M | 12.68M | 0 | |
| ROE | -0.47 | -0.54 | 0.08 | -0.32 | -0.7 | |
| Capex per share | -0.03 | -0.02 | -0.01 | -0.01 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0.03 | 0.02 | 0.01 | 0.02 | |
| Net income per share | -0.21 | -1.25 | -0.22 | -0.21 | -0.17 | |
| Operating cash flow per share | 0.08 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0.09 | 0 | 0 | 0 | 0 | |
| Cash per share | 1.45 | 1.35 | 1.7 | 1.56 | 1.36 | |
| Book value per share | 1.83 | 1.77 | 1.75 | 1.55 | 1.39 | |
| Tangible book value per share | 1.83 | 1.77 | 1.75 | 1.55 | 1.39 | |
| Share holders equity per share | 1.83 | 1.77 | 1.75 | 1.55 | 1.39 | |
| Interest debt per share | 0.05 | 0.86 | 0.02 | 0.06 | 0.06 | |
| Market cap | 105.47M | 96.78M | 82.7M | 45.39M | 30.92M | |
| Enterprise value | 93.79M | 90.55M | 67.66M | 32.94M | 25.06M | |
| P/E ratio | -5.33 | -0.78 | -3.46 | -1.99 | -1.6 | |
| Price to sales ratio | 1.05K | 127.68 | 139.23 | 213.08 | 69.18 | |
| POCF ratio | 55.8 | 0 | 0 | 0 | 0 | |
| PFCF ratio | 50.1 | 0 | 0 | 0 | 0 | |
| P/B Ratio | 2.5 | 2.2 | 1.71 | 1.05 | 0.8 | |
| PTB ratio | 2.5 | 2.2 | 1.71 | 1.05 | 0.8 | |
| EV to sales | 937.92 | 119.46 | 113.9 | 154.65 | 56.07 | |
| Enterprise value over EBITDA | -15.12 | -8.54 | -10.37 | -5.22 | -4.64 | |
| EV to operating cash flow | 49.63 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | 44.56 | 0 | 0 | 0 | 0 | |
| Earnings yield | -0.05 | -0.32 | -0.07 | -0.13 | -0.16 | |
| Free cash flow yield | 0.02 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0.02 | 0.01 | 0.01 | 0.04 | 0.04 | |
| Debt to assets | 0.02 | 0.01 | 0.01 | 0.03 | 0.04 | |
| Net debt to EBITDA | 1.88 | 0.59 | 2.31 | 1.97 | 1.08 | |
| Current ratio | 12.93 | 10.37 | 9.1 | 10.09 | 9.1 | |
| Interest coverage | -14.77 | 0.51 | 0 | 0 | 0 | |
| Income quality | -0.33 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 39.33 | 2.61 | 3.05 | 8.74 | 3.86 | |
| Research and developement to revenue | 42.17 | 12.38 | 8.94 | 21.93 | 9.33 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.11 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 2.15 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0.52 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 15.27 | 0 | 0 | 0 | 0 | |
| Graham number | 2.96 | 7.04 | 2.91 | 2.67 | 2.33 | |
| ROIC | -0.12 | 0.71 | -0.13 | -0.13 | -0.13 | |
| Return on tangible assets | -0.11 | -0.63 | -0.11 | -0.11 | -0.11 | |
| Graham Net | 1.52 | 1.33 | 1.51 | 1.31 | 1.14 | |
| Working capital | 39.73M | 36.76M | 45.92M | 40.97M | 36.65M | |
| Tangible asset value | 42.21M | 44.06M | 48.3M | 43.13M | 38.64M | |
| Net current asset value | 38.64M | 35.7M | 44.78M | 38.74M | 34.52M | |
| Invested capital | 0.02 | 0.01 | 0.01 | 0.04 | 0.04 | |
| Average receivables | 9.32M | 6.83M | 4.01M | 1.1M | 188.5K | |
| Average payables | 209K | 295K | 400K | 347.5K | 194K | |
| Average inventory | 0.5 | 0.5 | 0.5 | 0.5 | 0 | |
| Days sales outstanding | 7.07K | 689.37 | 334.09 | 0 | 75.91 | |
| Days payables outstanding | 5.36 | 3.25 | 7.81 | 4.51 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0.01 | 0.13 | 0.27 | 0 | 1.19 | |
| Payables turnover | 16.8 | 27.69 | 11.52 | 19.97 | 0 | |
| Inventory turnover | 4.22M | 0 | 5.31M | 0 | 0 | |
| ROE | -0.12 | -0.71 | -0.12 | -0.13 | -0.13 | |
| Capex per share | 0.01 | 0 | 0 | 0 | 0 |
SLGL Frequently Asked Questions
What is Sol-Gel Technologies Ltd. stock symbol ?
Sol-Gel Technologies Ltd. is a IL stock and trading under the symbol SLGL
What is Sol-Gel Technologies Ltd. stock quote today ?
Sol-Gel Technologies Ltd. stock price is $0.9436 today.
Is Sol-Gel Technologies Ltd. stock public?
Yes, Sol-Gel Technologies Ltd. is a publicly traded company.
Company Profile
- Volume Average 31.01K
- Market Capitalization 23.4M
- Employee 36
- CEO Dr. Alon Seri-Levy
- Headquarters Ness Ziona,IL
- IPO Date 2018-02-01
-
Website
https://www.sol-gel.com 
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
